Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo To Buy U3 Pharma Of Germany For $233.5 Million

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo says it plans to buy U3 Pharma of Germany for $233.5 million. The German bioventure specializes in antibodies as treatments for cancer. Daiichi's investment is seen as an effort to become a larger player in an area with a potential for high growth. The Japanese firm plans clinical trials of U3 Pharma drugs in Japan, the United States and Europe, drawing on the German company's ties with U.S. biotech Amgen. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts